OB33

OB33 is an antibody-based therapeutic in development as part of a collaboration between Boehringer Ingelheim and Oxford BioTherapeutics, aimed at treating solid tumors, with a specific initial focus on small cell lung cancer (SCLC) and neuroendocrine cancer (NEC)[1][8]. The drug was identified using Oxford BioTherapeutics’ proprietary OGAP-Verify discovery platform, which is designed for enhanced sensitivity and specificity in selecting novel therapeutic targets[2][3]. While detailed mechanisms of action remain undisclosed, OB33 is classified as an immunomodulator and, based on partner pipeline disclosures, is a T-cell engager (TCE) antibody targeting the Delta-like ligand 3 (DLL3) protein, which is expressed on the surface of certain cancer cells, notably in SCLC and NEC[1][8]. As of the latest available information, OB33 is in the preclinical development stage for solid tumors, with no orphan drug designation or evidence of regulatory approval[1][5]. Oxford BioTherapeutics’ partnership with Boehringer Ingelheim has yielded multiple oncology candidates, with OB33 representing the third asset to advance into IND-enabling studies under this collaboration[2][3][8].

Other names

OB-33OB33OB 33